SUMMARY

Upon performing the clinical study of (S)-2-[3-[N-[4-(4-fluorophenoxy)benzyl]carbamoyl]-4-methoxybenzyl]butanoic acid (hereinafter abbreviated as KRP-101), of which improvement in the lipidmetabolism is expected in a microdose, no oral solid dosage form that allows KRP-101 to be administered quantitatively has been embodied.

After mixing KRP-101 with additives (excipient, disintegrator and lubricant), the mixture is granulated, pressed into tablets and coated with coating agent, thereby film-coated tablets uniformly containing a small amount of KRP-101 are obtained, making it possible to administer a microdose of KRP-101 quantitatively on clinical study.